Cognitive side effects in rats caused by pharmacological agents used to prevent soman-induced lethality

European Journal of Pharmacology

Volumn 483, Issue 2-3, 2004, Pages 271-279

  Myhrer, Trond ^a   Enger, Siri ^a   Aas, Pål ^a  

^a NORWEGIAN DEFENCE RESEARCH ESTABLISHMENT FFI   (Norway)

Author keywords

(Rat); Cognitive impairment; Nerve agent; Physostigmine; Procyclidine; Prophylactic; Scopolamine

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; PHYSOSTIGMINE; PROCYCLIDINE; SCOPOLAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICHOLINERGIC EFFECT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENTIATION; INTERMETHOD COMPARISON; LETHALITY; LOW DRUG DOSE; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT;

EID: 0346056867     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.09.041     Document Type: Article

References (42)

1. Andersen J.M., Lindberg V., Myhrer T. Effects of scopolamine and D-cycloserine on non-spatial reference memory in rats. Behav. Brain Res. 129:2002;211-216.
2. Berlyne D.E. Novelty and curiosity as determinants of exploratory behaviour. Br. J. Psychol. 41:1950;68-80.
3. Berlyne D.E. Conflict, Arousal and Curiosity. 1960;McGraw-Hill, New York.
4. 14C pyridostigmine in the rat. Br. J. Pharmacol. 26:1966;393-402.
5. Blokland A. Acetylcholine: a neurotransmitter for learning and memory? Brains Res. Rev. 21:1996;285-300.
6. Capacio B.R., Shih T.-M. Anticonvulsant actions of anticholinergic drugs in soman poisoning. Epilepsia. 32:1991;604-615.
7. Carpentier P., Lambrinidis M., Blanchet G. Early dendritic changes in hippocampal pyramidal neurons (field CA1) of rats subjected to acute soman intoxication: a light microscopic study. Brain Res. 541:1991;293-299.
8. Cassel J.C., Kelche C. Scopolamine treatment and fimbriafornix lesions: mimetic effects on radial maze performance. Physiol. Behav. 46:1989;347-353.
9. D'Mello G.D., Sidell F.R. A modell for carbamate and organophosphate- induced emesis in humans. Neurosci. Biobehav. Rev. 15:1991;179-184.
10. Ennaceur A. Effects of lesions of the substantia/innominatal ventral pallidum, globus pallidus and medial septum on rats' performance in object recognition and radial-maze tasks: physostigmine and amphetamine treatments. Pharmacol. Res. 38:1998;251-263.
11. Ennaceur A., Meliani K. Effects of physostigmine and scopolamine on rats' performances in object-recognition and radial-maze tests. Psychopharmacology. 109:1992;321-330.
12. Ennaceur A., Neave N., Aggleton J.P. Neurotoxic lesions of the perirhinal cortex do not mimic the behavioural effects of fornix transection in the rat. Behav. Brain Res. 80:1996;9-25.
13. Frances H., Jacob J. Comparison of the effect of cholinergic and anticholinergic substances on the cerebral content of acetylcholine and motility of mice. Psychopharmacology. 21:1971;338-352.
14. Galbicka G., Ritchie V., Ferguson J., Didie E.R., Doan-Wellons Q. Effects of advanced candidate anticonvulsants under two rodent models of "counting" J. Appl. Toxicol. 21:2001;S109-S114.
15. Gao Z.G., Liu B.Y., Cui W.Y., Li L.J., Fan Q.H., Liu C.G. Anti-nicotinic properties of anticholinergic antiparkinson drugs. J. Pharm. Pharmacol. 50:1998;1299-1305.
16. Heise G.A., Hudson J.D. Effects of pesticides and drugs on working memory in rats: continuous delayed response. Pharmacol. Biochem. Behav. 23:1985;591-595.
17. Jang E.-J., Lee Y.-J., Chung S.-J., Shim C.-K. Nasal absorption of procyclidine in rats and dogs. Arch. Pharm. Res. 24:2001;219-223.
18. Jones R.W., Wesnes K.A., Kirby J. Effects of NMDA modulation in scopolamine dementia. Ann. N.Y. Acad. Sci. 640:1991;241-244.
19. Kim Y.-B., Cheon K.-C., Hur G.-H., Phi T.-S., Choi S.-J., Hong D., Kang J.-K. Effects of combinational prophylactics composed of physostigmine and procyclidine on soman-induced lethality, seizures and brain injuries. Environ. Toxicol. Pharmacol. 11:2002;15-21.
20. Kirkby D.L., Jones D.N.C., Higgins G.A. Influence of prefeeding and scopolamine upon performance in a delayed matching-to-position task. Behav. Brain Res. 67:1995;221-227.
21. Lallement G., Denoyer M., Collet A., Pernot-Mariono I., Baubichon D., Monmaur P., Blanchet G. Changes in hippocampal acetylcholine and glutamate extracellular levels during soman-induced seizures: influence of septal cholinoceptive cells. Neurosci. Lett. 139:1992;104-107.
22. Lennox W.J., Harris L.W., Talbot B.G., Anderson D.R. Relationship between acetylcholinesterase inhibition and efficacy against soman lethality. Life Sci. 37:1985;793-798.
23. Lyeth B.G., Ray M., Hamm R.J., Schnabel J., Saady J.J., Poklis A., Jenkins L.W., Gudeman S.K., Hayes R.L. Postinjury scopolamine administration in experimental traumatic brain injury. Brain Res. 569:1992;281-286.
24. McDonough J.H. Jr., Shih T.-M. A study of the N-Methyl-D-Aspartate antagonistic properties of anticholinergic drugs. Pharmacol. Biochem. Behav. 51:1995;249-253.
25. McDonough J.H. Jr., Shih T.-M. Neuropharmacological mechanisms of nerve agent induced seizure and neuropathology. Neurosci. Biobehav. Rev. 21:1997;559-579.
26. McNamara R.K., Skelton R.W. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brains Res. Rev. 18:1993;33-49.
27. Myhrer T. The role of medial and lateral hippocampal perforant path lesions and object distinctiveness in rats' reaction to novelty. Physiol. Behav. 42:1988;371-377.
28. Myhrer T. Exploratory behavior, reaction to novelty, and proactive memory in rats with temporo-entorhinal connections disrupted. Physiol. Behav. 45:1989;431-436.
29. Myhrer T. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brains Res. Rev. 41:2003;268-287.
30. Myhrer T., Enger S., Aas P. Soman-induced seizures in rats: possible treatment and prophylaxis. November 2002 Meeting on Prophylaxis and Therapy against Chemical Agents (TG-004) NATO/RTO Technical Proceedings, Oslo. 2002;NATO/RTO, Paris.
31. Myhrer T., Skymoen L.R., Aas P. Pharmacological agents, hippocampal EEG, and anticonvulsant effects on soman-induced seizures in rats. Neurotoxicology. 24:2003;357-367.
32. Santucci A.C., Kanof P.D., Haroutunian V. Effects of physostimine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats. Psychopharmacology. 99:1989;70-74.
33. Shih T.-M., McDonough J.H. Efficacy of biperiden and atropine as anticonvulsant treatment for organophosphorus nerve agent intoxication. Arch. Toxicol. 74:2000;165-172.
34. Sipos M.L., Burchnell V., Galbicka G. Dose-response curves and time-course effects of selected anticholinergics on locomotor activity in rats. Psychopharmacology. 147:1999;250-256.
35. Sipos M.L., Burchnell V., Galbicka G. Effects of selected anticholinergics on acoustic startle response in rats. J. Appl. Toxicol. 21:2001;S95-S101.
36. Somani S.M., Khalique A. Distribution and pharmacokinetics of physostigmine in rat after intramuscular administration. Fundam. Appl. Toxicol. 6:1986;327-334.
37. Stanhope K.J., McLenachan A.P., Dourish C.T. Dissociation between cognitive and/motivational derficits in the delayed matching to position test: effects of scopolamine, 8-OH-DPAT and EAA antagonists. Psychopharmacology. 122:1995;268-280.
38. Taylor P. Anticholinesterase agents. Gilman A.G., Goodman L.S., Rall T.W., Murad F. The Pharmacological Basis of Therapeutics. 6th ed. 1985;110-129 Macmillan, New York, USA.
39. Waelbroeck M., Camus J., Tastenoy M., Lambrecht G., Mutschler E.T.R., Christophe J. Stereoselectivivity of procyclidine binding to muscarinic receptor subtypes M1, M2 and M4. Eur. J. Pharmacol. 189:1990;135-142.
40. Walters G., Block R.G. Scopolamine effects on locomotor and exploratory activity in rats. Psychon. Sci. 17:1969;3-4.
41. Wetherell J., Hall T., Passingham S. Physostigmine and hyoscine improves protection against the lethal and incapacitating effects of nerve agent poisoning in the guinea-pig. Neurotoxicology. 23:2002;341-349.
42. Whiteman P.D., Fowle A.S.E., Hamilton M.J., Peck A.W., Bye A., Dean K., Webster A. Pharmacokinetics and pharmacodynamics of procyclidine in man. Eur. J. Clin. Pharmacol. 28:1985;73-78.